Business Wire

Calvin Klein, Inc. Announces Fall 2017 CALVIN KLEIN 205W39NYC Global Advertising Campaign

Del

Calvin Klein, Inc., a wholly owned subsidiary of PVH Corp. [NYSE: PVH], today announced the Fall 2017 CALVIN KLEIN 205W39NYC global multi-media advertising campaign. The campaign features the debut CALVIN KLEIN 205W39NYC collection by Chief Creative Officer Raf Simons.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170724005416/en/

FALL 2017 CALVIN KLEIN 205W39NYC GLOBAL ADVERTISING CAMPAIGN (Photo: © 2017 Willy Vanderperre)

FALL 2017 CALVIN KLEIN 205W39NYC GLOBAL ADVERTISING CAMPAIGN (Photo: © 2017 Willy Vanderperre)

Shot by photographer Willy Vanderperre, the visually striking campaign presents a cast of 22 models shot against a series of billboards that feature images from last season’s CALVIN KLEIN: American Classics campaign. The billboards of the previous campaign – which include works by artist Andy Warhol – were erected in the California desert in the days leading up to the shoot. The campaign is a study in art and artifice, of the real and the imagined, the mannered world of high fashion combined with a sense of the everyday. Ultimately, the campaign explores the cinematic and romantic outsider’s view of America, something of a dream world that has become concrete for Chief Creative Officer Raf Simons and Creative Director Pieter Mulier.

With over 850 million impressions planned across 22 global markets with an integrated media mix, this campaign will deliver on the continued evolution of CALVIN KLEIN under Simons. The brand will be featured extensively in fashion and lifestyle publications around the world during September’s fashion-focused issues. The re-appropriation of the successful American Classics campaign will come to life in large format and high impact outdoor in key locations such as New York, Paris, Brussels, China, Korea and Hong Kong.

The Fall 2017 CALVIN KLEIN 205W39NYC collection featured in the campaign is a mix of marching band uniforms, plastic coated protection, power broker tailoring, antique handcrafted quilting, workwear, and western wear. The line also includes the introduction of CALVIN KLEIN JEANS ESTABLISHED 1978 , a new designer denim line that will be housed under the CALVIN KLEIN 205W39NYC business. Pieces throughout the line are emblazoned with an exclusive patch that features a silhouette inspired by the iconic Richard Avedon image taken of actress Brooke Shields for Calvin Klein Jeans in 1981. The memorable campaign image debuted shortly after the launch of the Calvin Klein Jeans brand and the concept of designer jeans – in this way, CALVIN KLEIN JEANS ESTABLISHED 1978 celebrates both the history of the brand and its future.

Calvin Klein is a global lifestyle brand that exemplifies bold, progressive ideals and a seductive, and often minimal, aesthetic. We seek to thrill and inspire our audience while using provocative imagery and striking designs to ignite the senses.

Founded in 1968 by Calvin Klein and his business partner Barry Schwartz, we have built our reputation as a leader in American fashion through our clean aesthetic and innovative designs. Global retail sales of Calvin Klein brand products exceeded $8 billion in 2015 and were distributed in [over] 110 countries. Calvin Klein employs over 10,000 associates globally. We were acquired by PVH Corp. in 2003.

With a history going back over 130 years, PVH Corp. has excelled at growing brands and businesses with rich American heritages, becoming one of the largest apparel companies in the world. We have over 30,000 associates operating in over 40 countries with over $8 billion in revenues. We own the iconic Calvin Klein, Tommy Hilfiger, Van Heusen, IZOD, ARROW, Speedo*, Warner’s and Olga brands and market a variety of goods under these and other nationally and internationally known owned and licensed brands.

*The Speedo brand is licensed for North America and the Caribbean in perpetuity from Speedo International, Ltd.

EDITORIAL CREDIT: CALVIN KLEIN 205W39NYC

IMAGE CREDITS: © 2017 Willy Vanderperre

SOCIAL MEDIA: facebook.com/calvinklein ; calvinklein.tumblr.com ; google.com/+calvinklein ; youtube.com/calvinklein ; twitter.com/calvinklein ; instagram.com/calvinklein ; pinterest.com/calvinklein
snapchat: calvinklein
brand handle: @calvinklein

Contact information

Calvin Klein, Inc.
Alexandra Wagner, 212-292-9794
SVP, Corporate Communications
alexandrawagner@ck.com
or
Amanda Peña, 212-292-9223
Director, Corporate Communications
amandapena@ck.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Shell, bio-bean and Coffee-Drinkers Collaborate to Help Power London’s Buses20.11.2017 00:01Pressemelding

Shell and bio-bean announce that together they are helping to power some of London’s buses using a biofuel made partly from waste coffee grounds. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171119005060/en/ Shell and bio-bean announce that together they are helping to power some of London's buses using a biofuel made partly from waste coffee grounds (Photo: Business Wire) The B20 biofuel contains a 20% bio-component which contains part coffee oil. The biofuel is being added to the London bus fuel supply chain and will help to power some of the buses; without need for modification. Biofuel provides a cleaner, more sustainable energy solution for buses across London’s network by decreasing emissions1. “Our Coffee Logs have already become the fuel of choice for households looking for a

Samsung Bioepis Receives Regulatory Approval for Europe's First Trastuzumab Biosimilar, ONTRUZANT®19.11.2017 22:21Pressemelding

Samsung Bioepis Co., Ltd. today announced the European Commission’s (EC) marketing authorization of ONTRUZANT ® , a biosimilar referencing Herceptin ® (trastuzumab), for the treatment of early breast cancer, metastatic breast cancer and metastatic gastric cancer. ONTRUZANT ® is the first trastuzumab biosimilar to receive regulatory approval in Europe. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171119005066/en/ Christopher Hansung Ko, President & CEO of Samsung Bioepis. (Photo: Business Wire) The EC approval of ONTRUZANT ® applies to all 28 European Union (EU) member states and the European Economic Area (EEA) member states of Norway, Iceland and Liechtenstein. ONTRUZANT ® will be commercial

Cancer Patients, Survivors, Supporters and Caregivers Undertake UAE's First Relay for Life19.11.2017 16:31Pressemelding

Sharjah, the third largest of the United Arab Emirate’s seven emirates, was the host for the MENA region’s first ever ‘Global Relay for Life,’ (RFL) a 24-hour walkathon that is the biggest fundraising event for cancer in the world. Conducted in conjunction with the American Cancer Society, the event was organised by Friends of Cancer Patients (FoCP), a non-profit organisation that supports cancer patients and their families. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171119005048/en/ During MENA's first Global Relay For Life walkathon - Source: Friends of Cancer Patients Taking place November 17-18 at the American University Sharjah, the inaugural UAE RFL saw more than 2,000 relayers participating in the overnight event, with a large number of individuals and institutions involved including 52 sch

New Data Show Benefit of Tagrisso in Patients with EGFR-mutated Non-small Cell Lung Cancer and Central Nervous System Metastases18.11.2017 23:00Pressemelding

AstraZeneca today presented new data from a subgroup analysis of the Phase III FLAURA trial, which explored osimertinib as 1st-line therapy in patients with locally advanced or metastatic epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC). Results presented at the ESMO Asia 2017 Congress in Singapore showed that patients with central nervous system (CNS) metastases at baseline had a higher objective response rate with their brain metastasis and suggest a lower risk of CNS progression when treated with osimertinib, a third-generation, irreversible EGFR tyrosine kinase inhibitor (TKI), versus current standard-of-care EGFR-TKIs (erlotinib or gefitinib) [Abstract LBA5].1 The analysis included patients with ≥1 measurable and/or non-measurable CNS lesion present on baseline scan (as assessed by blinded independent central review), accounting for 23

New England Journal of Medicine Publishes Results of Phase III FLAURA Trial in the 1st-Line Treatment of EGFR-mutated Non-small Cell Lung Cancer18.11.2017 18:20Pressemelding

AstraZeneca today announced that the New England Journal of Medicine has published the positive results from the Phase III FLAURA trial which provide data for Tagrisso’s (osimertinib) use in the 1st-line treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC).1 The trial showed a statistically significant, clinically meaningful progression-free survival (PFS) advantage for osimertinib, a third-generation, irreversible EGFR tyrosine kinase inhibitor (TKI), compared with current 1st-line EGFR-TKIs, erlotinib or gefitinib.1 This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171118005044/en/ Dr. Suresh S. Ramalingam, Principal Investigator of the FLAURA trial, from the Winship Cancer Institute

Much-Anticipated CHTF 2017 Top 10 Products Are Unveiled18.11.2017 09:11Pressemelding

The 19th China Hi-Tech Fair (CHTF 2017), with the theme of “Innovation-Driven Development and Supply Quality Upgrade”, is taking place from November 16 to 21 at Shenzhen Convention and Exhibition Center. On the afternoon of November 10, the CHTF 2017 Top 10 Products were unveiled at the awards ceremony by Mr. Gao Zimin, Vice Mayor of Shenzhen City. A total of 322 entries competed for the honor Top 10 Products, and the voting lasted nearly 3 months. 60 candidate products in the fields of new energy, 3D print, flexible display, life sciences, unmanned vehicles and AI were shortlisted by the organizer, experts and media representatives and went for open voting online. The final Top 10 Products all represent the most advanced technologies in their respective sectors: the water-making device that can make water out of air, the smart sportswear that can monitor heartbeat and other

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom